Regenerative medicine company, CollPlant, has granted exclusive distribution rights to Arthrex, an orthopedic products company based in Florida, US, to commercialise its tendinopathy treatment device, Vergenix STR, in Europe, Middle-East, India and certain African markets.
The agreement comes into effect from 1 December 2016, with the first order scheduled for supply in the same month.
With an objective to incorporate digital health tools in clinical trials, Takeda Pharmaceutical has announced a strategic collaboration with Koneksa Health.
Pursuant to the agreement, Koneksa’s technology data platform, which enables remote collection of patient data, will be used by Takeda to integrate biosensor and wearable technology in its early-stage clinical studies.
The collaboration enables Takeda to leverage technologies, gain access to novel data streams, and, eventually, conduct more patient-centric clinical trials.
Median Technologies, an oncology-related imaging software and services provider, intends to raise gross process of €19.6m ($21.83m) in private placement of its common stock shares, to be subscribed to by Furui Medical Science Company Luxembourg.
The subscriber will hold 13.01% of the share capital and 13.03% of the voting rights of Median, upon completion of the transaction.
The proceeds from the offering will be used to develop business opportunities in China and also for working capital and other general corporate purposes.
Beijing Beidestar Technology and Development (BDS) has received exclusive distribution rights from ImmersiveTouch to commercialise its neurosurgery and ophthalmology products in China.
The distribution agreement calls for an initial purchase commitment for ImmersiveTouch simulation systems.
Medical equipment company, Theralase Technologies, intends to raise gross proceeds of C$6m ($4.47m) in a public placement of its 20,000,000 shares priced at C$0.3 ($0.22) each.
The amount raised from the transaction, which is expected to close on or about 10 November 2016, will be used by the company for research and development (R&D), product commercialisations, and for other corporate purposes.
Image: Vergenix STR. Photo: Courtesy of CollPlant Ltd.